MC
ICPT

Marcus Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Marcus Capital’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-5,200
Closed -$565K – 50
2016
Q4 		$565K Sell
5,200
-5,075
-49% -$605K 0.61% 41
2016
Q3 		$1.69M Buy
10,275
+25
+0.2% +$3.94K 1.62% 31
2016
Q2 		$1.46M Hold
10,250
– – 1.54% 30
2016
Q1 		$1.32M Buy
+10,250
New +$1.21M 1.45% 33

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marcus Capital's ICPT Position: Q1 2017 in Review

Marcus Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2017, closing a stake of 5,200 shares — an estimated $565K sold.

Marcus Capital first reported a position in ICPT in Q1 2016 and held it in 4 quarters. The position peaked at $1.69M in Q3 2016. 150 funds tracked by Wall St. Rank hold ICPT as of Q1 2017.

  • Marcus Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Marcus Capital sold 5,200 Intercept Pharmaceuticals, Inc. shares in Q1 2017, an estimated $565K.
  • Marcus Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2016 and held it in 4 quarters.
  • Marcus Capital's Intercept Pharmaceuticals, Inc. position peaked at $1.69M in Q3 2016.
  • 150 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2017.

Based on Marcus Capital's 13F filing for Q1 2017, filed 9 May 2017.